• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Rutgers receives $26M antibiotics grant from NIH

Rutgers receives $26M antibiotics grant from NIH

April 30, 2014
CenterWatch Staff

The National Institute of Allergy and Infectious Diseases (NIAID) of the NIH has selected infectious disease expert David Perlin, executive director of the Public Health Research Institute at Rutgers New Jersey Medical School, to lead a major research effort aimed at developing new forms of antibiotics to regain the upper hand over deadly bacteria that have become resistant to current treatments.  

With a five-year grant of up to $26 million, Perlin will participate in the Centers of Excellence for Translational Research (CETR), a public-private partnership that brings together prominent scientists from Rutgers as well as other institutions.

"We are poised for a new era of antimicrobial discovery," said Perlin. "By joining together researchers from academia and the commercial sector in a highly interactive collaborative partnership, and providing comprehensive resources that support drug discovery, we can overcome many of the barriers that limit antibiotic development and begin to reinvigorate the drug pipeline."

When modern antibiotics were introduced in the 1940s to help control deadly bacterial disease, they were greeted as wonder drugs. Now, just a few generations later, bacteria have adapted and become resistant to many of those drugs, creating a profound new threat to human health.

According to the Centers for Disease Control and Prevention, more than two million people are sickened every year in the U.S. with antibiotic-resistant infections resulting in at least 23,000 deaths, and health experts predict that serious illness with enhanced death tolls will continue to rise without major new drug discoveries. With few new drugs being developed, many serious infections have become largely untreatable.

Senior leaders of the research team assembled by Perlin, who also is executive director of the Regional Biocontainment Laboratory (RBL) at Rutgers, include Sean Brady, a chemical biologist at the Rockefeller University in New York City; David Alland, an infectious disease researcher at Rutgers New Jersey Medical School; Joel Freundlich, a medicinal chemistry expert from New Jersey Medical School; and Richard Ebright, Principal Investigator in Rutgers' Waksman Institute of Microbiology.

Cubist, the first industry member of the consortium, will collaborate to advance new discoveries into the clinical development stage. The recently-formed Institute for Infectious and Inflammatory Diseases at New Jersey Medical School also will play a key role in the partnership, as will other major components of the newly-aligned Rutgers scientific community. 

CETR will include sophisticated core resources through which highly promising early concept molecules developed by the research team can be turned into potential antibiotics suitable for clinical testing. The center will have access to facilities that include the Rutgers Regional Biocontainment Laboratory, an NIH-designated national research center for pathogens such as high-threat bioterror agents that can be engineered to be resistant to existing antibiotics. The team also will seek to develop new bacteria-fighting approaches that are designed to sidestep, or at least significantly slow, development of bacterial resistance in the future. Perlin and a Scientific Advisory Committee will guide the overall program.

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing